AccurKardia, an innovator in ECG-based diagnostics technology, today announced that its AccurECG TM software platform has ...

The China 3D cardiac mapping market has showcased significant growth, with its valuation increasing from $55.55 million in 2019 to a projected $150.59 million by 2027. This report offers a detailed ...

Pulsed field ablation dominated discussions and scientific sessions at Heart Rhythm 2025 in San Diego with researchers and ...

Boston Scientific, Medtronic, Abbott and J&J unveiled new data for their PFA devices in tandem with the Heart Rhythm ...

In the single-arm PULSAR IDE study of 162 people, the novel PFA system demonstrated 78% primary effectiveness, defined as 12-month freedom from a documented 30-second episode of Afib/atrial ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

(RTTNews) - Abbott (ABT) announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the ...

defined as 12-month freedom from a documented 30-second episode of Afib/atrial flutter/atrial tachycardia, failure of pulmonary vein isolation (PVI), cardioversion, antiarrhythmic drug use ...

That receptiveness has also included an embrace of greater housing density that Marks said would “send hearts in Manly or Ku-ring-gai aflutter”, but meant there weren’t “tumbleweeds ...